BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Secures C$13.29M Through Previously Announced Offering

September 9, 2020 10:55:03

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today confirmed that it has closed its previously announced offering of units for aggregate gross proceeds of approximately C$13.29 million. According to the update, the company issued 15,640,000 units, each at a price of C$0.85, with each unit consisting of one common share of the company and ½ of one common share purchase warrant, with each whole warrant entitling the holder to purchase one share, at the price of C$1.10 per share, until September 9, 2023. “Over the last four years, LexaGene has constantly been gaining momentum. This financing will allow us to complete the transformation of going from strictly an R&D company, to one that is supporting manufacturing and sales,” Dr. Jack Regan, CEO and founder of LexaGene, said in the news release. “This is a very exciting time to be part of LexaGene as we look to make an impact on multiple market verticals.”

To view the full press release, visit

About LexaGene Holdings Inc.

LexaGene is a molecular diagnostics company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press “go.” The MiQLab analyzer delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time “PCR” assays onto the instrument to target any genetic target of interest. For more information, visit the company’s website at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork